Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Date publication

avril 2015

Journal

Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric

Tous les auteurs :
Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, Deconinck E, Nagler A, Mohty M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25424330

Résumé

Fludarabine plus busulfan (FB) and fludarabine plus melphalan (FM) are 2 widely used reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (allo-SCT).

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Busulfan, administration & dosage, Combined Modality Therapy, Female, Follow-Up Studies, Graft vs Host Disease, etiology, Hematopoietic Stem Cell Transplantation, adverse effects, Humans, Leukemia, Myeloid, Acute, mortality, Lymphocyte Depletion, Male, Melphalan, administration & dosage, Middle Aged, Neoplasm Recurrence, Local, etiology, Neoplasm Staging, Prognosis, Remission Induction, Retrospective Studies, Survival Rate, Transplantation Conditioning, adverse effects, Vidarabine, administration & dosage, Young Adult

Référence

Cancer. 2015 Apr;121(7):1048-55